Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Non-Ischemic Central Retinal Vein Occlusion

In brief

This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.

Key facts

Study ID
NCT01295112
Run by
Texas Retina Associates
People needed
68
Starts
2011-05-01
Expected to finish
2015-10-01
Last updated by the study team
2025-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.